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Abstract
Background:  The primary objective of this study was to investigate if supplementary lactobacilli
treatment could improve the initial cure rate after vaginal clindamycin therapy, and secondly, if lactobacilli
as repeated adjunct treatment during 3 menstrual cycles could lengthen the time to relapse after initial
cure.
Methods: Women (n = 100) with bacterial vaginosis diagnosed by Amsel criteria were after informed
consent offered vaginal clindamycin therapy followed by vaginal gelatine capsules containing either 109
freeze-dried lactobacilli or identical placebo capsules for 10 days during 3 menstrual cycles in a double-
blind, randomized, placebo-controlled trial.
Results: The initial intent to treat (ITT) analysis for the one-month cure rate was 64% in the lactobacilli
group and 78% in the placebo group (p > 0.05). However, any patient with missing or unclassified smears
at the initial visit who continued the study and whose next smear indicated a cure was included in the
cured group; the study also excluded two of the patients in the lactobacilli group who reported that they
did not take any vaginal capsules. With consideration to these population changes, the initial cure rate
would be 77% in the lactobacilli group. The 76 cured women were followed for 6 menstrual cycles or until
relapse within that time span. At the end of the study, 64.9% (24/37) of the lactobacilli treated women
were still BV-free compared to 46.2% (18/39) of the placebo treated women. Comparison of the two
groups regarding "Time from cure to relapse" was statistically significant (p = 0.027) in favour of the
lactobacilli treatment. Adjuvant therapy with lactobacilli contributed significantly to avoidance of relapse
with a proportional Hazard Risk ratio (HR) of 0.73 (0.54–0.98) (p < 0.05)
Conclusion: The study shows that supplementary treatment combining two different strains of probiotic
lactobacilli does not improve the efficacy of BV therapy during the first month of treatment, but for women
initially cured, adjunct treatment of lactobacilli during 3 menstrual cycles lengthens the time to relapse
significantly in that more women remained BV free at the end of the 6-month follow up.
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Background
Bacterial vaginosis (BV) is a disease with unknown aetiol-
ogy, characterized by loss or reduction of lactobacilli and
increased overgrowth of other bacteria. It is one of the
most frequent vaginal infections, and its most common
symptom is malodorous discharge. BV is associated with
adverse pregnancy outcome. Treatment in early pregnancy
will reduce the incidence of extreme preterm deliveries
[1].
The recommended treatment regimes for BV are oral or
vaginal metronidazole or vaginal clindamycin [2]. Treat-
ment efficacy is supposedly high. In a meta-analysis, the
expected cure rate after one month was 70%–80% for
metronidazol [3] and 82% for clindamycin [4]. However,
in clinical practice these high efficacy rates have not been
observed. Based on our own review of published data, the
efficacy is not more than 60% [5]. Thus it is likely that the
published efficacy results are higher than the actual clini-
cal figures. In a recent follow-up study, only 48% were BV
free 12 months after therapy [6]. Consequently there is a
need for a BV treatment regime that will improve the
rather low efficacy of the present therapy.
Lactic-acid-producing bacilli are part of the normal bacte-
rial microbiota of the vagina and have a physiological role
in maintaining a low pH (<4.5) and protecting against
invasion by other micro-organisms [7]. However, what
kind of lactobacilli are commensally in the vagina is a
matter of debate. Traditionally Lactobacillus acidophilus has
been considered to be dominant. Recent studies supple-
menting traditional methods with genotyping through
rapid amplified polymorphic DNA (RAPD) analysis, have
shown the most common vaginal lactobacilli species to be
L. crispatus, L. gasseri, L. iners and L. jensinii [8]. So far trials
that aimed to re-implant lactobacilli as treatment for BV
have not been convincing. One double-blind, rand-
omized, placebo-controlled trial showed that women
who received ovules with L. acidophilus were initially
cured, but the next menstruation was followed by a BV
relapse giving a cure rate of only 18% after 4 weeks [9].
The treatment suggestion by Reid et al. [10] to restore
asymptomatic BV to lactobacilli microbiota by giving oral
capsules of L. fermentum and L. casei var. rhamnosus suc-
ceeded in 37% of the treated cases compared to 13% who
were given placebo. In a recent study from Nigeria, the
same strains of lactobacilli ingested orally after a one-
week course of oral metronidazole cured 88% of women
with BV compared to 45% in the metronidazole/placebo
group [11].
The use of adjuvant lactobacilli after antibiotic treatment
using vaginal tampons with freeze- dried lactobacilli did
not increase the efficacy. The one-month cure rate after 3
days of vaginal clindamycin followed by lactobacilli tam-
pons cured 56% compared to 62.5% for clindamycin and
placebo tampons [12].
The primary objective of this study was to investigate if
supplementary lactobacilli treatment could improve the
initial cure rate after vaginal clindamycin therapy, and sec-
ondly, if lactobacilli as repeated adjunct treatment during
3 menstrual cycles could lengthen the time to relapse after
initial cure.
Methods
Study population
The study was conducted at an out-patient private gynae-
cological clinic in Drammen, Norway from February 2004
until May 2006. All women with symptomatic BV who
visited the clinic and fulfilled the inclusion criteria were
consecutively invited to participate in a prospective, dou-
ble-blind, placebo-controlled study of lactobacilli supple-
menting the clindamycin therapy. Of the eligible patients,
two rejected participation the other signed an informed
consent.
Inclusion criteria were: regularly menstruating women 18
years of age or older, with normal gynaecological status,
not pregnant or breast feeding, and without signs of other
genital tract infections.
Exclusion criteria were: patients with hormonal IUD with-
out regular menstruation; women with clinical Candida
infection or Trichomonas vaginalis infection.
Study sample
Populations of 100 patients were randomized into two
groups of 50 patients. The mean age was 34.3 years with a
total range of 18.8–53.6 yrs. The initial symptoms were
86% malodorous discharge, 70% increased discharge,
14% itching, and 11% burning. There were no differences
in background variables. The diagnosis of BV based on
Amsel criteria were 95% fulfilling the criteria: typical dis-
charge, 94% positive whiff test, 99% had presence of clue
cells (one missing data), and 100% had a pH > 4.5.
Clinical method
At inclusion in the study, women underwent a routine
gynaecological examination with non-lubricated specu-
lum including vaginal ultrasound. A sample of vaginal
secretion was analysed for vaginal pH using special pH
strips (range 3.8–5.0). The BV diagnosis was based on
Amsel criteria [13], i.e. fulfil at least 3 of 4 criteria: thin
homogenous discharge, vaginal pH above 4.5, positive
amine test, presence of clue cells during microscopical
investigation. Any presence of motile curved rods,
Mobiluncus was recorded during this first visit. The motile
bacteria had to be observed in active motion in an
opposed direction to the rest of the sample. Vaginal fluidBMC Women's Health 2008, 8:3 http://www.biomedcentral.com/1472-6874/8/3
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was sampled and air-dried. At inclusion, vaginal samples
for Chlamydia trachomatis infection were done with strand-
displacement amplification (CT amplified DNA assay;
Becton-Dickinson) according to the local laboratory rou-
tine. Samples for Neiseria gonorrhea were done only when
there was medical reason to suspect its presence.
Treatment
After signing the informed consent document, the partici-
pants were given a seven-day course of daily 2% vaginal
clindamycin cream (Pfizer Norway Ltd) directly followed
by vaginal gelatine capsules containing 108–9 freeze-dried
lactobacilli or placebo capsules of identical appearance,
sufficient for 10 days or until menstruation commenced;
these capsules were randomized in blocks of 10. After
each menstruation, the treatment with vaginal lactobacilli
capsules or placebo was repeated during 10 days for three
cycles. Thus the treatment regime included one treatment
course with clindamycin followed by four lactobacilli/pla-
cebo courses, one within the same menstrual cycle and the
other during the next three consecutively cycles.
The trial drugs
The lactobacilli used are commercially available EcoVag®
Vaginal capsules (Bifodan A/S, Denmark) containing two
types of lactic acid bacteria L. gasseri (Lba EB01-DSM
14869) minimum of 108–9 CFU/capsules and L. rhamnosus
(Lbp PB01-DSM 14870) minimum of 108–9CFU/cap-
sules. Both are lactobacilli strains cultured from healthy
women in Norway. Other ingredients: lactitol monohy-
drate, gelatine, cornstarch, xanthan gum, glucose anhy-
drous, titanium dioxide and magnesium stearate.
The placebo vaginal capsules of identical appearance con-
tained sorbitol, gelatine, potato starch, and magnesium
stearate.
Follow up
After each menstruation, the patient self-swabbed a speci-
men of vaginal fluid and stroked the cotton tip on a glass
slide: the sample was then air dried and submitted in a
sealed envelope to the clinic according to a previously
described method [12]. The vaginal sample was collected
after cessation of bleeding and before starting of treatment
with the vaginal capsules. Women who were considered
still to be infected with BV after the first menstruation
were re-treated with vaginal clindamycin and excluded
from the study. The remaining participants were asked to
continue to swab vaginal samples and insert vaginal cap-
sules (lactobacilli or placebo) after each menstruation.
The nurse affiliated with the study conducted a telephone
interview with each participant to document treatment
complications and concomitant medication. If the patient
had failed to submit a sample of vaginal fluid at the right
time, the sample was recorded as missing and she was
reminded to send in a new sample after the next menstru-
ation. Ideally, a total of 6 vaginal samples was collected
from each participant. After four menstrual cycles, the par-
ticipant was scheduled for a follow up visit to the clinic.
This visit was booked to take place at least one menstrua-
tion after the final treatment with lactobacilli/placebo.
Normally the vaginal samples were taken once every 28
days and the follow up time of 6 menstrual cycles thus
would be 5 and half months but for some women, 6 men-
strual cycles exceeded 6 months. Therefore, we report this
6-month follow up as number of BV free days between
cured and relapse, as well as menstrual cycles.
Microscopical investigation
Each vaginal sample was rehydrated with normal saline
solution and surveyed under a phase contrast microscope
with 400× magnification and an area of 0.016 mm2. A
rough count of bacteria was recorded as well as the pres-
ence of clue cells together with number of vaginal leuco-
cytes. Each slide was classified by two methods: according
to Hay/Ison classification [14,15] and to Nugent [16].
Dual classifications were made for a comparative study,
the findings of which will be published elsewhere.
Definition of cure
The treatment was considered a cure when the Hay/Ison
score was 1, a score of 2 was designated as improved and
a score of 3 was classed as treatment failure. A Hay/Ison
group of 0 and 4 were regarded as equal as a score of 1
during the first follow up periods. Treatment efficacy is
based on reported both as cure after one month, and as
length of time to relapse illustrated with Kaplan-Meier
survival analysis, i.e. as number of BV free days between
cured and relapse, and as menstrual cycles. Re-treatment
with clindamycin was given in those cases with micro-
scopical evidence of BV i.e. a Hay/Ison score of 3.
We had the possibility to grow vaginal culture to ascertain
if the lactobacilli recovered from certain participants were
the same strain as those provided via the lactobacilli cap-
sules. This investigation was done by the Statens Serum
Institute (SSI) in Copenhagen, Denmark without any
knowledge on their part of the treatment the women had
received.
Study design
The initial part of the study was open, whereby patients
were treated with vaginal clindamycin for seven days; it
continued thereafter as a double-blind, randomized, pla-
cebo-controlled trial with parallel group design. The
patients were equally allocated 1:1 to either lactobacilli
capsules or placebo capsules of identical appearance by
block randomization with a fixed block size of 10. The
capsules were given for 10 days during three consecutive
menstrual cycles.BMC Women's Health 2008, 8:3 http://www.biomedcentral.com/1472-6874/8/3
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Statistical methods
Not all patients collected a vaginal fluid sample every
month, but all who sampled at least once were included
in the analysis. In case of missing data during the follow
up, the procedure "last observation carried forward"
(LOCF) was used. In case of missing data from a visit for
a relapsed patient, the observation from the following
visit was transferred back. This procedure was used in
order not to over-estimate the effect. The variable "days
from cured to relapse" has been calculated in days and is
given by Kaplan-Meier plot. Analysis using the number of
menstrual cycles instead of days from cured to relapse was
also done. Additionally, the proportional HR ratio with
95% confidence interval (CI) is given [17] and Fisher
exact test. All comparisons between and within groups
were performed two-tailed with a significance level of 5%.
All study personnel were blinded to the treatment
throughout the study and all the data were collected and
recorded in data sheets before the code of the active or pla-
cebo treatment was added. Thereafter no changes in the
data sheet were allowed.
A difference in relapse rate between the lactobacilli group
and the placebo group of at least 20% was considered
clinically relevant. Power analyses with a significance level
of 5% and a power of 80%, resulted in at least 46 patients
having to be included in each of the two treatment arms
to show a 20% difference.
All the analysis in this study was performed in accordance
with the principal of intent to treat (ITT).
Ethical
The study was approved by the southeast regional Ethics
Committee in Oslo, Norway. To recruit women with BV,
advertisements in local newspapers requested women suf-
fering from malodorous discharge to contact the study
group. All patients did signed a written informed consent
document.
Results
The initial cure after the first menstruation was 64% (32/
50) in the lactobacilli group versus 74% (37/50) in the
placebo group (p = 0.12). However any patient with miss-
ing or unclassified smears at the initial visit who contin-
ued the study and whose next smear indicated a cure was
included in the cured group. The cure rate would thus be
74% (37/50), (95% CI: 59.7 – 85.4) in the lactobacilli
group versus 78% (39/50), (95% CI: 64.0 – 88.5) in the
placebo group (p = 0.82). By omitting two of the patients
in the lactobacilli group who reported that they did not
take any vaginal capsules, the initial cure rate would be
37/48 (77%) in the lactobacilli group. Of the remaining
24 women, 15 were re-treated as failed treatment cases
and nine dropped out of the study.
The 76 women initially classified as cured were now fol-
lowed until their 6th menstrual cycle or until relapse.
There was a significant difference (p = 0.027) in favour of
the lactobacilli treated women in time duration from
cured to relapse which is illustrated in Kaplan-Meier plot
(Figure 1). Expressed as number of menstrual periods
from cured to relapse, the findings showed a similar curve
that did not reach significance (p = 0.06) (Figure 2).
At the end of the study, 64.9% (24/37) of the lactobacilli
treated women were pronounced cured compared to
46.2% (18/39) of the placebo treated women giving a sig-
nificant HR ratio of 0.73 (95% CI: 0.54–0.98) (p = 0.042)
(see Flowchart in Additional file 1).
The presence of motile curved rods Mobiluncus showed a
tendency to affect the results since there were lower cure
rates among women who exhibited mobiluncus in the wet
smear at the first visit (Table 1). However this difference
did not reach statistical significance (p = 0.14 Fisher exact
test).
Ten patients had taken other antibiotics during the study
period, six before the first follow-up visit, four from the
lactobacilli group and two from the placebo group. The
antibiotics were given for Chlamydia infection (2), for
upper respiratory infection (3) and for urinary tract infec-
tion (1). The exclusion of these patients did not affect the
study result. Two of the patients who took antibiotics did
so after their relapse. Two patients took antibiotics that
could have influenced the results. One woman given pla-
cebo received broad-spectrum antibiotics because of
upper respiratory infection half way through the study.
Time from cured to relapse of BV in days Figure 1
Time from cured to relapse of BV in days. The results are 
given as a Kaplan-Meier plot expressing the probability of no 
relapse before the given day. The lactobacilli-treated women 
have a significantly longer time until relapse with a log rank p 
= 0.027
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Her BV was cured after the antibiotics; the other patient
did not show any effect of the antibiotics.
Totally 146 patients came to our clinic with malodorous
discharge. Of these, 102 fulfilled the inclusion criteria
although two decided not to join the study, 10 had a BV
infection but did not have regular menstrual periods, 6
did not fulfil all of the Amsel criteria, 3 had other diagno-
sis, 9 had normal discharge, and 18 (38%) had normal
pH and normal lactobacilli seen in the smear together
with Candida albicans blastospores and mycelia. For these
women, treatment with fluconazole successfully reduced
the symptomatic malodour.
A total of 14 patients in the lactobacilli group and 12 in
the placebo group reported adverse events (AE) during the
study. The reported events were headache, menorrhagia,
haemorrhoids, influenza, bronchitis, whiplash, asthma,
and urinary tract infection. The study did not detect any
difference between the two groups regarding type nor fre-
quency of AE. Among the AE reported as probable or
almost certain was one woman who stopped treatment
because of vaginal discomfort due to suspected allergy in
lactobacilli group and another due to itching in the pla-
cebo group. Five patients in the lactobacilli group and
four patients in the placebo group were treated with
antimycotic drugs for symptomatic candida infection.
It was possible to culture only seven lactobacilli strains. Of
these strains, four were L. gasseri species, all from women
treated with lactobacilli. These four strains were tested
using 500 bp sequences in the 16S V1 region with 100%
concordance to the original strain given to the women.
Discussion
This is the second study to show that supplement therapy
with two different lactobacilli strains could improve the
efficacy of the BV treatment. The cure rate improved at the
6th month from 46% to 65%, a nearly 20% difference that
may be of clinical importance. There was, however no
improvement in the initial cure rate. The ITT cure rate was
64% (32/50) in the lactobacilli group versus 78% (39/50)
in the placebo group. However any patient with missing
or unclassified smears at the initial visit who continued
the study and whose next smear indicated a cure was
included in the cured group and by omitting two of the
patients in the lactobacilli group who reported that they
did not take any vaginal capsules, the initial cure rate
would be 37/48 (77%) in the lactobacilli group, thus
there are no difference between the lactobacilli and the
placebo group in the initial cure. This cure rate (77–78%)
is higher than earlier reported [5] but one reason could be
that we report the cure after the first menstruation and not
after 28 days. The first menstruation could occur already
after 14 days. Another hypothesis is that the antibiotic
effect of clindamycin lasts longer than the seven days of
treatment. That is feasible if clindamycin concentrates in
the vagina though a counter-current circulation similar to
that which has been demonstrated for penicillin [18]. In
such case, the antibiotic effects of clindamycin would still
be present when the first lactobacilli capsules are intro-
duced. The lactobacilli strains are sensitive for antibiotics
such as clindamycin. This could explain that there was no
difference in the initial cure rate. A broad spectrum of
antibiotics such as clindamycin was chosen as the trial
drug since it eradicates all native lactobacilli strains mak-
ing it possible to introduce new strains of lactobacilli; this
is not the case for metronidazole which has no antibiotic
effect on the lactobacilli. Presumably it is also possible
that the strains used in this study could be upgraded to a
strain that more rapidly will increase the restoration of the
normal vaginal microbiota.
In the active capsules, the excipients lactitol and glucose
were chosen both as diluents and as nutritive growth
medium for the lactobacilli. Since the placebo capsules
should not contain nutritive growth medium, sorbitol
was used together with potato starch. Potato starch was
selected instead of cornstarch, in the placebo capsules due
to our experience that it gives the best capsule-filling abil-
Time from cured to relapse of BV in menstrual months Figure 2
Time from cured to relapse of BV in menstrual months. The 
results are given as a Kaplan-Meier plot expressing the prob-
ability of no relapse before the given month. The lactobacilli-
treated women have a borderline-significant longer time until 
relapse with a log rank p = 0.06.
0,0
0,1
0,2
0,3
0,4
0,5
0,6
0,7
0,8
0,9
1,0
P
r
o
b
a
b
i
l
i
t
y
 
o
g
 
n
o
 
r
e
l
a
p
s
e
0 1 2 3 4 5 6
Time from cured to relapse in menstrual periods
		

	

Table 1: The frequency of relapse related to the presence of 
motile curved rods, mobiluncus at the inclusion visit
Mobiluncus Relapse No relapse Total
No 19 (40%) 29 48
Yes 16 (57%) 12 28
Total 35 41 76
P = 0.14 Fisher exact test.BMC Women's Health 2008, 8:3 http://www.biomedcentral.com/1472-6874/8/3
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ity when combined with sorbitol. The lactobacilli and the
placebo capsules had identical appearance. Although we
cannot be certain, we do not believe that the active excip-
ients in the placebo capsules would affect the results of the
study.
With the aim of reducing the number of relapsing
patients, Sobel et al. started to treat women with recurrent
BV with vaginal metronidazole gel for ten days rather than
the normal five days [19]. Women who responded to this
therapy were treated with metronidazole gel or placebo
twice weekly for a 4-month period, followed by another 3
months without therapy – a study design very similar to
our own. At 4 months, 75% were cured in the treatment
group compared to 59% in the placebo group, but after 7
months, only 49% in the treatment group versus 25% in
the placebo group were still BV free. Our results with 65%
cured in the lactobacilli treated group and 46% in the pla-
cebo group is slightly better. There is however a difference
between the two studies. Sobel et al. deliberately recruited
women with recurrent BV as opposed to our study which
had a random recruitment. However our material
included many women who had been treated for BV
before entering the study; also it also included partici-
pants who were treated for BV for the very first time. Based
upon the result of this study it can be concluded that the
suppressive treatment with lactobacilli is not better than
suppressive treatment with metronidazole gel, but falls
within the same range. However, there are ecological
advantages to using lactobacilli instead of antibiotics for
longer duration. Maybe a combination of both treatment
regimes should be used in the most therapy-resistant
cases. Results from the Nigerian study where the use of
oral lactobacilli improved the cure by 40% after 30 days
are very encouraging [11].
One must bear in mind that we have not inquired about
any new sexual partner or partners nor have we treated
any of the sexual partners. However, in our study group
there are very few other sexually transmitted diseases as
we had no case of T. vaginalis infection or N. gonorrhoea,
and only 3 patients with C. trachomatis infection. Whether
or not BV should be regarded as a sexually transmitted dis-
ease is controversial and a matter of major professional
debate as was discussed in a previous review [20]. Still the
question arises from patients with recurrent BV whether
the sexual partner should be treated simultaneously or
not. There is no documentation for this treatment
approach in the literature [5] although many clinicians
will treat the partner of the infected patient.
We had a dropout rate of 10% in this 6-month follow up
study which is statistically considered to be an acceptable
figure. Sobel et al. had 12% [19] dropouts and Bradshaw
et al. had 6% [6].
The strength of our study is that all patients were recruited
at the same clinic and that 98 of 100 patients were
recruited by the same investigator and that all smears and
all follow up were done by one investigator. Drawbacks
are that we recruited women with recurrent BV as well as
women with initial BV infections and we had no knowl-
edge of the number of sex partners.
The reported adverse events are mild and transient and no
difference between placebo or lactobacilli groups is indi-
cated. Nine patients had been treated for symptomatic
candida infections. As most other treatment studies for BV
report that 10% of the patients have a symptomatic cand-
ida infection, our results are in concordance with other
studies [5].
The culturing of vaginal flora sampled from cured patients
was disappointing. Of seven lactobacilli strains cultured,
four were L. gasseri, the same species given to the women
in the treatment. However, as we had only sequenced 500
bp in the V1 region of the 16S, we can not with certainty
claim that this lactobacilli strains is the exactly the same as
the L. gasseri (Lba EB01-DSM 14869) given to the women.
One possible reason that we only could grow seven lacto-
bacilli cultures could be that the median transportation
time from the clinic to the microbiological laboratory in
Copenhagen was seven days. This is too long. The ship-
ping was done by regular mail. Further studies have to be
done to assure that lactobacilli introduced in treatment
can colonize the vagina.
Our results indicate that it takes a long time for some
women to suffer a relapse. Some patients had an increase
in number of bacteria per vision field with Gardnerella
morphotype from 0 at first month to 50, 100, 500, 2000
and finally 4000 at 6 months when the relapse was obvi-
ous. This could indicate that this is not a new infection but
rather an infection that was suppressed to a level below
the detection threshold of our clinical methods. With
slow growing bacteria such as Mobiluncus this could
quite feasible. Our study is the first to report a tendency to
lower cure rate among women harbouring Mobiluncus as
opposed to women without any motile curved rods.
We used Hay/Ison scoring for the diagnosis of BV [14,15]
as we earlier encountered limitations in the use of Nugent
scoring. This particularly applies to treatment studies and
is even more pronounced when clindamycin vaginal
cream is the selected treatment. Clindamycin vaginal
cream eradicates almost all bacteria in the vagina, and
greatly reduces the lactobacilli morphotype bacteria, giv-
ing the Nugent score of around 4. This means that the
smear can be incorrectly interpreted as demonstrating
intermediate flora. On the other hand, if there are only
five Gardnerella morphotype bacteria per vision field, theBMC Women's Health 2008, 8:3 http://www.biomedcentral.com/1472-6874/8/3
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Nugent score would increase from 0 to 3 even when there
are more than 500 lactobacilli morphotype bacteria [21].
The Hay/Ison [14,15] classification is better adapted to
follow up treatment results. This must be taken into con-
sideration when discussing treatment efficacy.
Even though this was not in the protocol for our study,
symptomatic malodour has not to our knowledge been
reported as symptoms of candida infections before.
Conclusion
In conclusion, this study shows that supplement treat-
ment with two different strains of probiotic lactobacilli
does not improve the efficacy of BV therapy during the ini-
tial first month. After lactobacilli treatment given during
three menstrual cycles, there is a significant improvement
in "time to relapse" so more women remain cured, i.e. are
BV-free, after 6 months.
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